RATIONALE AND OBJECTIVES: Our purpose was to investigate a "blood pool" contrast agent for abdominal and thoracic MR angiography by comparison with standard ionic and nonionic gadolinium-based contrast agents, which redistribute into the extracellular fluid compartment. METHODS: Abdominal and thoracic MR angiography was performed in three adult dogs using a three-dimensional spoiled gradient echo pulse sequence before and after intravenous administration of one of three gadolinium-based contrast agents (gadopentetate dimeglumine, gadobutrol, and gadomer-17). Each compound was tested at five different doses in all three dogs. Quantitative analysis of signal-to-noise ratio (SNR) was performed in the aorta, inferior vena cava (IVC), liver, spleen, kidney (medulla and cortex), fat, and muscle. RESULTS: Gadomer-17 improved visualization of vascular anatomy at doses of 0.025, 0.05, 0.1, and 0.2 mmol/kg with three-fold greater aorta SNR during the arterial phase and more than four-fold greater aorta and IVC SNR during the equilibrium phase, in comparison with gadopentetate dimeglumine and gadobutrol at equal doses. CONCLUSIONS: Gadomer-17 is a promising contrast agent for both arterial phase and equilibrium phase MR angiography.
RATIONALE AND OBJECTIVES: Our purpose was to investigate a "blood pool" contrast agent for abdominal and thoracic MR angiography by comparison with standard ionic and nonionic gadolinium-based contrast agents, which redistribute into the extracellular fluid compartment. METHODS: Abdominal and thoracic MR angiography was performed in three adult dogs using a three-dimensional spoiled gradient echo pulse sequence before and after intravenous administration of one of three gadolinium-based contrast agents (gadopentetate dimeglumine, gadobutrol, and gadomer-17). Each compound was tested at five different doses in all three dogs. Quantitative analysis of signal-to-noise ratio (SNR) was performed in the aorta, inferior vena cava (IVC), liver, spleen, kidney (medulla and cortex), fat, and muscle. RESULTS:Gadomer-17 improved visualization of vascular anatomy at doses of 0.025, 0.05, 0.1, and 0.2 mmol/kg with three-fold greater aorta SNR during the arterial phase and more than four-fold greater aorta and IVC SNR during the equilibrium phase, in comparison with gadopentetate dimeglumine and gadobutrol at equal doses. CONCLUSIONS:Gadomer-17 is a promising contrast agent for both arterial phase and equilibrium phase MR angiography.
Authors: Scott H Medina; Venkatesh Tekumalla; Maxim V Chevliakov; Donna S Shewach; William D Ensminger; Mohamed E H El-Sayed Journal: Biomaterials Date: 2011-03-22 Impact factor: 12.479
Authors: Bruno Marchand; Philippe C Douek; Philippe Robert; Claire Corot; Jean Pierre Roux; Patrice Adeleine; Marcela Hernandez-Hoyos; Yannick Cremillieux; Maciej Orkisz; Emmanuelle Canet Journal: MAGMA Date: 2002-06 Impact factor: 2.533
Authors: Zoltán Jászberényi; Loïck Moriggi; Philipp Schmidt; Claudia Weidensteiner; Rainer Kneuer; André E Merbach; Lothar Helm; Eva Tóth Journal: J Biol Inorg Chem Date: 2007-01-10 Impact factor: 3.862